Organization | Andalusian Initiative in Advanced Therapies

Andalusian Initiative in Advanced Therapies Report issue

Government Phase 1 Phase 2 Phase 3

Founded: Granada Spain (2008)

Organization Overview

First Clinical Trial

2009

NCT00987363

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Alternative names

Iniciativa Andaluza en Terapias Avanzadas

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous mononuclear stem cell (2 trials)

Drugs in Phase 2 Trials (6)

allogeneic adipose derived mesenchymal stem cell (2 trials)

allogeneic blood cells (1 trial)

autologous bone marrow derived mesenchymal cells (3 trials)

autologous mesenchymal stem cells (2 trials)

bone autograft (2 trials)

Filgrastim (neupogen) (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic lymphocytes (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Amyotrophic Lateral Sclerosis (Phase 2)

Atherosclerosis (Phase 3)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Occlusion (Phase 3)

Fecal Incontinence (Phase 2)

Heart Diseases (Phase 3)

Heart Failure (Phase 3)

Ischemia (Phase 2)

Motor Neuron Disease (Phase 2)

Myocardial Ischemia (Phase 3)

Sclerosis (Phase 2)

Ventricular Dysfunction (Phase 3)

Viremia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial APIs: 8